Regencell Net Tangible Assets from 2010 to 2026
| RGC Stock | USD 31.22 2.20 7.58% |
Net Tangible Assets | First Reported 2010-12-31 | Previous Quarter 19.6 M | Current Value 20.6 M | Quarterly Volatility 10 M |
Check Regencell Bioscience financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Regencell Bioscience's main balance sheet or income statement drivers, such as Depreciation And Amortization of 335.8 K, Interest Expense of 19.8 K or Selling General Administrative of 2.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.6 K. Regencell financial statements analysis is a perfect complement when working with Regencell Bioscience Valuation or Volatility modules.
Regencell | Net Tangible Assets | Build AI portfolio with Regencell Stock |
Analyzing Regencell Bioscience's Net Tangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Tangible Assets has evolved provides context for assessing Regencell Bioscience's current valuation and future prospects.
Latest Regencell Bioscience's Net Tangible Assets Growth Pattern
Below is the plot of the Net Tangible Assets of Regencell Bioscience Holdings over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Regencell Bioscience's Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Regencell Bioscience's overall financial position and show how it may be relating to other accounts over time.
| Net Tangible Assets | 10 Years Trend |
|
Net Tangible Assets |
| Timeline |
Regencell Net Tangible Assets Regression Statistics
| Arithmetic Mean | 5,017,570 | |
| Coefficient Of Variation | 199.31 | |
| Mean Deviation | 9,222,175 | |
| Median | (1,838,521) | |
| Standard Deviation | 10,000,460 | |
| Sample Variance | 100T | |
| Range | 24.6M | |
| R-Value | 0.82 | |
| Mean Square Error | 34.4T | |
| R-Squared | 0.68 | |
| Significance | 0.00005 | |
| Slope | 1,629,778 | |
| Total Sum of Squares | 1600.1T |
Regencell Net Tangible Assets History
About Regencell Bioscience Financial Statements
Regencell Bioscience stakeholders use historical fundamental indicators, such as Regencell Bioscience's Net Tangible Assets, to determine how well the company is positioned to perform in the future. Although Regencell Bioscience investors may analyze each financial statement separately, they are all interrelated. For example, changes in Regencell Bioscience's assets and liabilities are reflected in the revenues and expenses on Regencell Bioscience's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Regencell Bioscience Holdings. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Tangible Assets | 19.6 M | 20.6 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:Check out the analysis of Regencell Bioscience Correlation against competitors. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Will Biotechnology sector continue expanding? Could Regencell diversify its offerings? Factors like these will boost the valuation of Regencell Bioscience. Anticipated expansion of Regencell directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Regencell Bioscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Regencell Bioscience using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Regencell Bioscience's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Regencell Bioscience's market price to deviate significantly from intrinsic value.
It's important to distinguish between Regencell Bioscience's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Regencell Bioscience should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Regencell Bioscience's market price signifies the transaction level at which participants voluntarily complete trades.